Ulcerative Colitis Video Perspectives

Dubinsky reports receiving consulting fees from AbbVie, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Genentech, Gilead, Janssen, Pfizer, Prometheus Biosciences, Roche, Takeda and UCB; participating in contracted research for AbbVie, Janssen, Pfizer and Prometheus Biosciences; holding ownership interest/stock in Trellus Health; and receiving licensing fees from Takeda.

February 01, 2023

1 min watch

Save

VIDEO: Recent approvals for ulcerative colitis

Transcript

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

In terms of the most recent approvals for UC specifically, we've had a busy couple years actually. We had ozanimod, which is was our first S1P receptor modulator that was approved for UC in June of 2021.

And then in March of 2022, we had a second small molecule oral, which was upadacitinib, which is a JAK1-selective JAK inhibitor. So, you know, we had two great, you know, additions in the small molecule world, and I'm hopeful that in 2023, fingers crossed, there's gonna be an IL-23 specifically for UC and possibly a second S1P receptor modulator. So lots of exciting things that happened in the last year and a half or so and expected in the year of 2023.